As for SMARCA4, in non-small cell lung cancer, SMARCA4 deletion is sensitive to combination of etoposide and DZNep (EZH2 inhibitor) (Fillmore et al. 2015). Here, EZH2 is linked to non-small cell lung carcinoma.